Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN5500 for Neuropathic Pain in Cancer Patients
NCT00474916Phase 2Completed
- Sponsor
- DARA BioSciences
- Start
- Jun 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of KRN-5500 in neuropathic pain (2 arms), sponsored by DARA BioSciences. Primary endpoint: Average pain intensity over the previous 24 hours. Started Jun 2006; status: completed.
02
Drugs
KRN-5500
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT00474916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474916.